BioAffinity Technologies Inc (NASDAQ: BIAF)’s stock price has increased by 27.33 compared to its previous closing price of 0.25. However, the company has seen a 24.24% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-06-26 that SAN ANTONIO–(BUSINESS WIRE)– #BIAF–bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
Is It Worth Investing in BioAffinity Technologies Inc (NASDAQ: BIAF) Right Now?
Additionally, the 36-month beta value for BIAF is 2.52. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIAF is 20.25M and currently, short sellers hold a 3.80% ratio of that float. The average trading volume of BIAF on June 26, 2025 was 12.57M shares.
BIAF’s Market Performance
BIAF stock saw an increase of 24.24% in the past week, with a monthly gain of 14.52% and a quarterly increase of 9.85%. The volatility ratio for the week is 9.12%, and the volatility levels for the last 30 days are 15.01% for BioAffinity Technologies Inc (BIAF). The simple moving average for the last 20 days is 12.55% for BIAF stock, with a simple moving average of -64.37% for the last 200 days.
BIAF Trading at -3.30% from the 50-Day Moving Average
After a stumble in the market that brought BIAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.56% of loss for the given period.
Stock Fundamentals for BIAF
Current profitability levels for the company are sitting at:
- -1.09 for the present operating margin
- 0.34 for the gross margin
The net margin for BioAffinity Technologies Inc stands at -1.11. The total capital return value is set at -4.52. Equity return is now at value -290.85, with -143.25 for asset returns.
Based on BioAffinity Technologies Inc (BIAF), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -4.93. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is -114.15.
Currently, EBITDA for the company is -8.33 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.12. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 1.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.55.
Conclusion
In conclusion, BioAffinity Technologies Inc (BIAF) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
